Subscribe To
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Rosen, a highly recognized law firm, encourages cs disco, inc. investors to secure counsel before important deadline in securities class action – law
NEW YORK, Oct. 14, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of CS Disco, I...
October 14, 2023, 6:55 pm
Rosen, leading trial attorneys, encourages archer aviation inc. investors to secure counsel before important deadline in securities class action – achr
NEW YORK, Oct. 14, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Archer Aviati...
October 14, 2023, 4:45 pm
Cogent biosciences presents preclinical data highlighting precision oncology pipeline at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantage...
October 14, 2023, 4:30 pm
Napco security technologies (nssc) shareholders alerted to securities fraud class action
Hagens Berman, National Trial Attorneys, Encourages Investors to the Contact Firm SAN FRANCISCO, Oct. 14, 2023 (GLOBE NEWSWIRE) — Hagens Berman urge...
October 14, 2023, 4:22 pm
The buildclub: ‘bold new era’ webinar
Discover The BuildClub’s game-changing approach to construction material sourcing PALO ALTO, Calif., Oct. 14, 2023 (GLOBE NEWSWIRE) — via IBN – ...
October 14, 2023, 3:00 pm
Driving into digital age: ferrari accepting cryptocurrency in us, europe next
Ferrari’s latest shift in payment options underscores the brand’s commitment to innovation and its dedication to providing a seamless and cutting-...
October 14, 2023, 1:44 pm
Cenovus energy: preferred shares could yield 8-12% upon reset
Cenovus Energy is a large integrated oil and gas producer in Canada with strong financial results and high dividend coverage ratios. The Series 3 pref...
October 14, 2023, 11:40 am
How weight loss drugs could impact stocks
Weight loss drugs, such as Novo Nordisk's (NVO) Ozempic and Wegovy, continue to grow in popularity. With many brand and retailer CEOs signaling the hi...
October 14, 2023, 11:00 am